Nalaganje...
Idelalisib in the management of lymphoma
Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide...
Shranjeno v:
| izdano v: | Blood |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5161010/ https://ncbi.nlm.nih.gov/pubmed/27252232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-02-702761 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|